Gilead Sciences [GILD] vs Johnson & Johnson [JNJ] Detailed Stock Comparison
Gilead Sciences
NASDAQ
Loading...
Johnson & Johnson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gilead Sciences wins in 10 metrics, Johnson & Johnson wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Gilead Sciences | Johnson & Johnson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 22.21 | 19.24 | Johnson & Johnson |
| Price-to-Book Ratio | 7.11 | 5.57 | Johnson & Johnson |
| Debt-to-Equity Ratio | 127.34 | 64.69 | Johnson & Johnson |
| PEG Ratio | 1.02 | 1.07 | Gilead Sciences |
| EV/EBITDA | 11.49 | 15.51 | Gilead Sciences |
| Profit Margin (TTM) | 21.87% | 25.00% | Johnson & Johnson |
| Operating Margin (TTM) | 39.16% | 28.91% | Gilead Sciences |
| EBITDA Margin (TTM) | 39.16% | 28.91% | Gilead Sciences |
| Return on Equity | 33.40% | 30.21% | Gilead Sciences |
| Return on Assets (TTM) | 12.62% | 7.61% | Gilead Sciences |
| Free Cash Flow (TTM) | $10.31B | $18.06B | Johnson & Johnson |
| Dividend Yield | 3.25% | 2.47% | Gilead Sciences |
| 1-Year Return | 30.70% | 16.03% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 4.84 | 4.83 | Johnson & Johnson |
| Enterprise Value | $158.54B | $469.28B | Johnson & Johnson |
| EV/Revenue Ratio | 5.49 | 5.18 | Johnson & Johnson |
| Gross Profit Margin (TTM) | 78.80% | 67.87% | Gilead Sciences |
| Revenue per Share (TTM) | $23 | $38 | Johnson & Johnson |
| Earnings per Share (Diluted) | $5.07 | $9.44 | Johnson & Johnson |
| Beta (Stock Volatility) | 0.38 | 0.39 | Gilead Sciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Gilead Sciences vs Johnson & Johnson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gilead Sciences | 1.94% | -0.39% | -1.91% | -0.85% | -1.19% | 20.33% |
| Johnson & Johnson | 1.44% | 4.64% | 4.45% | 19.56% | 19.71% | 29.13% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gilead Sciences | 30.70% | 71.97% | 73.18% | 9.85% | 508.48% | 830.64% |
| Johnson & Johnson | 16.03% | 16.09% | 23.19% | 95.01% | 194.13% | 203.20% |
News Based Sentiment: Gilead Sciences vs Johnson & Johnson
Gilead Sciences
News based Sentiment: MIXED
October was a largely positive month for Gilead, with strong earnings and analyst upgrades offset by potential drug pricing pressures. The company's significant investments in R&D and manufacturing signal a commitment to long-term growth, but the Biktarvy pricing issue introduces a notable risk factor, creating a mixed overall investment narrative.
Johnson & Johnson
News based Sentiment: POSITIVE
September was a remarkably positive month for Johnson & Johnson, driven by a series of FDA approvals, promising clinical trial results, a significant analyst upgrade, and recognition for sustainability efforts. These developments collectively strengthen the investment case and suggest continued growth potential for the company.
Performance & Financial Health Analysis: Gilead Sciences vs Johnson & Johnson
| Metric | GILD | JNJ |
|---|---|---|
| Market Information | ||
| Market Cap | $139.74B | $437.40B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 7,201,150 | 9,642,260 |
| 90 Day Avg. Volume | 6,413,223 | 8,329,883 |
| Last Close | $112.71 | $188.65 |
| 52 Week Range | $83.98 - $121.83 | $140.68 - $189.78 |
| % from 52W High | -7.49% | -0.60% |
| All-Time High | $123.37 (Jun 22, 2015) | $189.78 (Oct 03, 2025) |
| % from All-Time High | -8.64% | -0.60% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.06% |
| Quarterly Earnings Growth | 0.21% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.22% | 0.25% |
| Operating Margin (TTM) | 0.39% | 0.29% |
| Return on Equity (TTM) | 0.33% | 0.30% |
| Debt to Equity (MRQ) | 127.34 | 64.69 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.84 | $32.61 |
| Cash per Share (MRQ) | $4.88 | $7.84 |
| Operating Cash Flow (TTM) | $9.87B | $23.03B |
| Levered Free Cash Flow (TTM) | $8.84B | $11.08B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.25% | 2.47% |
| Last 12-Month Dividend | $3.91 | $3.72 |
Valuation & Enterprise Metrics Analysis: Gilead Sciences vs Johnson & Johnson
| Metric | GILD | JNJ |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 22.21 | 19.24 |
| Forward P/E | 15.16 | 17.13 |
| PEG Ratio | 1.02 | 1.07 |
| Price to Sales (TTM) | 4.84 | 4.83 |
| Price to Book (MRQ) | 7.11 | 5.57 |
| Market Capitalization | ||
| Market Capitalization | $139.74B | $437.40B |
| Enterprise Value | $158.54B | $469.28B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.49 | 5.18 |
| Enterprise to EBITDA | 11.49 | 15.51 |
| Risk & Other Metrics | ||
| Beta | 0.38 | 0.39 |
| Book Value per Share (MRQ) | $15.84 | $32.61 |
Financial Statements Comparison: Gilead Sciences vs Johnson & Johnson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GILD | JNJ |
|---|---|---|
| Revenue/Sales | $6.67B | $23.74B |
| Cost of Goods Sold | $1.54B | $7.63B |
| Gross Profit | $5.13B | $16.12B |
| Research & Development | $1.38B | $3.52B |
| Operating Income (EBIT) | $2.49B | $6.81B |
| EBITDA | $3.28B | $9.21B |
| Pre-Tax Income | $1.65B | $6.49B |
| Income Tax | $334.00M | $954.00M |
| Net Income (Profit) | $1.32B | $5.54B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GILD | JNJ |
|---|---|---|
| Cash & Equivalents | $7.93B | $38.47B |
| Total Current Assets | $16.90B | $71.55B |
| Total Current Liabilities | $12.34B | $56.90B |
| Long-Term Debt | $22.15B | $38.36B |
| Total Shareholders Equity | $19.08B | $78.11B |
| Retained Earnings | $10.93B | N/A |
| Property, Plant & Equipment | $7.96B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GILD | JNJ |
|---|---|---|
| Operating Cash Flow | $1.56B | $6.35B |
| Capital Expenditures | $-104.00M | $-795.00M |
| Free Cash Flow | $1.65B | $3.37B |
| Debt Repayment | $-1.76B | $-2.87B |
| Common Stock Repurchase | $-730.00M | $-2.13B |
Short Interest & Institutional Ownership Analysis
| Metric | GILD | JNJ |
|---|---|---|
| Shares Short | 18.25M | 22.05M |
| Short Ratio | 2.97 | 2.84 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 7,201,150 | 9,642,260 |
| Average Daily Volume (90 Day) | 6,413,223 | 8,329,883 |
| Shares Outstanding | 1.25B | 2.41B |
| Float Shares | 1.24B | 2.40B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.91% | 0.74% |
Dividend Analysis & Yield Comparison: Gilead Sciences vs Johnson & Johnson
| Metric | GILD | JNJ |
|---|---|---|
| Last 12-Month Dividend | $3.91 | $3.72 |
| Last 12-Month Dividend Yield | 3.25% | 2.47% |
| 3-Year Avg Annual Dividend | $3.30 | $3.97 |
| 3-Year Avg Dividend Yield | 0.91% | 0.75% |
| 3-Year Total Dividends | $9.91 | $11.92 |
| Ex-Dividend Date | Sep 15, 2025 | Feb 18, 2025 |